New PET tracer could sharpen diagnosis of blood cancers

NCT ID NCT04504526

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a special PET scan using a tracer called 68Ga-Pentixafor can better detect and predict the course of blood cancers like lymphoma, multiple myeloma, and leukemia. The tracer targets a protein on cancer cells, potentially offering clearer images than standard scans. Researchers will compare the results with traditional FDG PET/CT and track patient survival over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 68Ga-Pentixafor, injected once for PET/CT imaging
What this could lead to
If successful, this imaging method could improve how doctors diagnose and predict the course of blood cancers, leading to more personalized treatment.
What could go wrong
This is an early-phase study with only 50 participants, so results may not apply to all patients. The tracer's accuracy compared to standard scans is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.